ZLAB Jan 2025 17.500 call
| Previous close | 6.40 |
| Open | 5.89 |
| Bid | 3.00 |
| Ask | 5.20 |
| Strike | 17.50 |
| Expiry date | 2025-01-17 |
| Day's range | 5.89 - 6.40 |
| Contract range | N/A |
| Volume | |
| Open interest | 13 |
Business WireZai Lab Initiates Global Phase 2 Clinical Trial Evaluating ZL-1102 As a Topical Treatment for Chronic Plaque Psoriasis
SHANGHAI & CAMBRIDGE, Mass., May 22, 2024--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that the first patient has been dosed in a global Phase 2 clinical trial (NCT06380907) evaluating the efficacy and safety of the company’s internally developed anti-IL-17 investigational therapy, ZL-1102, for the treatment of chronic plaque psoriasis (CPP). ZL-1102 is a novel human VH antibody fragment (Humabody®) targeting the IL-17 cytokine. Emphasizing its unique approach, ZL-1102 is being de
Business WireZai Lab and Innoviva Specialty Therapeutics Announce NMPA Approval for XACDURO® (Sulbactam-Durlobactam or SUL-DUR) for Hospital-Acquired and Ventilator-Associated Pneumonia Caused by Acinetobacter Baumannii-Calcoaceticus Complex in China
SHANGHAI & CAMBRIDGE, Mass. & WALTHAM, Mass., May 20, 2024--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) and Innoviva Specialty Therapeutics today announced that China’s National Medical Products Administration (NMPA) has approved Zai Lab’s New Drug Application (NDA) for XACDURO® (sulbactam-durlobactam) for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (HABP/VABP) caused by susceptible isolates of Acinetobacter baumannii-calcoaceticus complex
GuruFocus.comInsider Sale: Chief Legal Officer of Zai Lab Ltd (ZLAB) Sells Shares
Edmondson Frazor Titus III, Chief Legal Officer of Zai Lab Ltd (NASDAQ:ZLAB), executed a sale of 10,000 shares of the company on May 14, 2024.
